Soleno Therapeutics, Inc. | Company Profile, Culture & Jobs

Company overview

At Soleno Therapeutics, we believe in the power of science, advocacy, and community. We are honored to stand alongside the Prader-Willi syndrome (PWS) community and are committed to making a meaningful difference in the lives of those impacted by rare diseases. The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received FDA-approval in March 2025. For more information, please visit soleno.life.

Founded in 1999

Redwood City, California, USA

162 employees (11 in marketing)

soleno.life

0% recommend to a friend

0% positive business outlook

People

Hiring activity

Open marketing jobs over time

5 open now

Headcount trend

Company growth over the last 12 months

Funding

Total funding

$569.2M

Last raise

$200M

Post IPO Equity, 8 months ago

Funding history

Jul 2025

Post IPO Equity Soleno Therapeutics · $200M

Dec 2024

Post IPO Debt Soleno Therapeutics · $50M

May 2024

Post IPO Equity Soleno Therapeutics · $158.7M

Sep 2023

Post IPO Equity Soleno Therapeutics · $129M

Mar 2022

Post IPO Equity Soleno Therapeutics · $15M

Audience

Monthly website visitors

8.9K

Month over month0%

Quarter over quarter0%

Top sourceDirect (30.9%)

Ad budget per month$0.0

Average search rank49.2

Traffic source mix

Direct

30.9%

Search

21.9%

News

Wolfe Research Initiates Soleno Therapeutics (SLNO) Coverage with Outperform Rating, $75 PT, Dismisses Patient Slowdown Concerns

Nov 21, 2025 • Yahoo Finance

Wolfe Research Initiates Coverage of Soleno Therapeutics (SLNO) with Outperform Recommendation

Nov 19, 2025 • Nasdaq

Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid

Nov 13, 2025 • GlobeNewswire

Links

soleno.life

Crunchbase

Glassdoor

Soleno Therapeutics, Inc. insights

Company and marketing-team signals from saved company data and employee profiles. Use this before you apply, interview, or negotiate.

Founded

1999

Headquarters

Redwood City, California

Employees

51-200

52.8% growth last 12mo

Marketing team

11

7% of company

7 saved employee profiles are linked to this company.

Company stability and risk

Shows a quick risk view from growth, funding age, and news.

Main result

Low risk

Late-stage · Growing 52.8% last 12 months · More mature · Recently funded

Trend

2022-03-28 -> 2026-01-26

Headcount (12 months)

+52.8%

Last funding round

8 months ago

Negative news (120 days)

0

Risk score0/7

Website traffic

Shows traffic size, change, and traffic sources.

Monthly website visitors

8.9K

Month over month0%

Quarter over quarter0%

Top sourceDirect (30.9%)

Traffic source mix

Direct

30.9%

Search

21.9%

Social

Competitors and search

Shows competitors and key search metrics in one view.

Main result

170 competitor sites

Search traffic: 777 organic clicks / 0 paid clicks

Organic competitors

0

Paid competitors

0

Keyword change

+50

Ad budget per month

$0.0

Average search rank

49.2

LinkedIn followers

Shows follower count and growth.

LinkedIn followers

Follower count and growth

Job openings

Shows open jobs, growth, and role changes.

Main result

1 open jobs

Open jobs trend: —

Trend

2024-01-01 -> 2026-02-01

Open jobs growth

—

Biggest role change

—

Latest open role

Manager / Senior Manager, Marketing Operations

Marketing team size

Shows saved marketing team size.

11

7% of the company • 7 saved marketing people

First hire or larger team

Shows if this looks like one hire or a bigger team.

Looks like larger team

Based on saved marketing team size: 11.

Glassdoor ratings

Shows saved Glassdoor ratings.

Glassdoor ratings

Overall rating

0 / 5

Work-life balance

0 / 5

Culture

0 / 5

Diversity & inclusion

0 / 5

Recommend to a friend

0%

Positive business outlook

0%

Funding

Shows saved funding data.

Total funding

$569.2M

Last raise

Post IPO Equity

8 months ago

Funding details

Amount raised

$569.2M

Last round

Post IPO Equity

Last fundraise

8 months ago

News

Shows saved company news.

Wolfe Research Initiates Soleno Therapeutics (SLNO) Coverage with Outperform Rating, $75 PT, Dismisses Patient Slowdown Concerns

Nov 21, 2025 • Yahoo Finance

Wolfe Research Initiates Coverage of Soleno Therapeutics (SLNO) with Outperform Recommendation

Nov 19, 2025 • Nasdaq

Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid

Nov 13, 2025 • GlobeNewswire

Loading insights...

Headcount +52.8% year over year

Dec 2018

Post IPO Equity Soleno Therapeutics · $16.5M

Social

7.8%

Referral

3.6%

Paid referral

0.7%

LinkedIn followers

Follower count and growth

Total followers

15.8K

12-mo growth

+82.9%

Monthly growth

+19.2%

Salaries

Help build salary transparency at Soleno Therapeutics, Inc.

Share your compensation anonymously to see full data.

Contribute

Open positions5 open marketing positions

Associate Field Medical Marketing Director

Soleno Therapeutics, Inc.

San Diego, CA (On-site)

$173K/yr - $222K/yrIn-houseFull-timeMid level8+ years exp.

2 hrs ago

Associate Field Medical Marketing Director

Soleno Therapeutics, Inc.

USA (On-site)

$173K/yr - $222K/yrIn-houseFull-timeSenior level8+ years exp.

9 hrs ago

Associate Field Medical Marketing Director

Soleno Therapeutics, Inc.

San Diego, CA (On-site)

$173K/yr - $222K/yrIn-houseSalaried-FtSenior level8+ years exp.

13 days ago

Associate Director, Marketing

Soleno Therapeutics, Inc.

Redwood City, CA (On-site)

$195K/yr - $225K/yrIn-houseSalaried-FtSenior level8+ years exp.

6 months ago

Associate Director, Field Marketing

Soleno Therapeutics, Inc.

USA (Remote)

$195K/yr - $225K/yrIn-houseSalaried-FtDirector/executive7+ years exp.

6 months ago

Soleno Therapeutics, Inc. insights

Company and marketing-team signals from saved company data and employee profiles. Use this before you apply, interview, or negotiate.

Founded

1999

Headquarters

Redwood City, California

Employees

51-200

52.8% growth last 12mo

Marketing team

11

7% of company

7 saved employee profiles are linked to this company.

Company stability and risk

Shows a quick risk view from growth, funding age, and news.

Main result

Low risk

Late-stage · Growing 52.8% last 12 months · More mature · Recently funded

Trend

2022-03-28 -> 2026-01-26

Headcount (12 months)

+52.8%

Last funding round

8 months ago

Negative news (120 days)

0

Risk score0/7

Website traffic

Shows traffic size, change, and traffic sources.

Monthly website visitors

8.9K

Month over month0%

Quarter over quarter0%

Top sourceDirect (30.9%)

Traffic source mix

Direct

30.9%

Search

21.9%

Social

Competitors and search

Shows competitors and key search metrics in one view.

Main result

170 competitor sites

Search traffic: 777 organic clicks / 0 paid clicks

Organic competitors

0

Paid competitors

0

Keyword change

+50

Ad budget per month

$0.0

Average search rank

49.2

LinkedIn followers

Shows follower count and growth.

LinkedIn followers

Follower count and growth

Job openings

Shows open jobs, growth, and role changes.

Main result

1 open jobs

Open jobs trend: —

Trend

2024-01-01 -> 2026-02-01

Open jobs growth

—

Biggest role change

—

Latest open role

Manager / Senior Manager, Marketing Operations

Marketing team size

Shows saved marketing team size.

11

7% of the company • 7 saved marketing people

First hire or larger team

Shows if this looks like one hire or a bigger team.

Looks like larger team

Based on saved marketing team size: 11.

Glassdoor ratings

Shows saved Glassdoor ratings.

Glassdoor ratings

Overall rating

0 / 5

Work-life balance

0 / 5

Culture

0 / 5

Diversity & inclusion

0 / 5

Recommend to a friend

0%

Positive business outlook

0%

Funding

Shows saved funding data.

Total funding

$569.2M

Last raise

Post IPO Equity

8 months ago

Funding details

Amount raised

$569.2M

Last round

Post IPO Equity

Last fundraise

8 months ago

News

Shows saved company news.

Wolfe Research Initiates Soleno Therapeutics (SLNO) Coverage with Outperform Rating, $75 PT, Dismisses Patient Slowdown Concerns

Nov 21, 2025 • Yahoo Finance

Wolfe Research Initiates Coverage of Soleno Therapeutics (SLNO) with Outperform Recommendation

Nov 19, 2025 • Nasdaq

Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid

Nov 13, 2025 • GlobeNewswire

7.8%

Referral

3.6%

Paid referral

0.7%

Total followers

15.8K

12-mo growth

+82.9%

Monthly growth

+19.2%